[Asia Economy Reporter Hyunseok Yoo] Bioinfra Life Sciences announced on the 16th that it has received approval for listing from the Korea Exchange and is scheduled to officially commence trading on the KONEX market starting from the 22nd.
Bioinfra Life Sciences was established in 2001. By integrating biomarker discovery and bioinformatics technology, the company has developed and is providing the 'i-FINDER,' a multi-protein marker-based service product that predicts the risk of eight major cancers. Additionally, to offer the best cancer risk prediction service, it is developing an in vitro early cancer diagnosis method that combines the advantages of multi-protein markers and genetic markers.
The company is also developing anticancer drugs. A company representative emphasized, "We are developing anticancer drugs that apply metabolic anticancer agents, known as fourth-generation anticancer drugs, and drug delivery systems utilizing ultrasound."
Bioinfra plans to enter the beauty market in the future. To this end, in the fourth quarter, it will launch new products including a skin beauty device applying drug delivery platform technology to the skin and a product utilizing microbubbles. The company also plans to expand into the functional cosmetics market.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
